Issue 95

psilocybin in thailand

The Study of Psilocybin in Thailand

Earlier this month, the Thai government announced it will develop depression treatments from psilocybin-producing fungi.

The World Health Organization estimates 1.5 million Thai people suffer from depression including over a million women, for which depression is the leading cause of lower life expectancy.

Somsak Thepsuthin, Thailand’s Justice Minister, said declassifying psilocybin could present a significant economic opportunity for the country’s agricultural sector –  with fresh mushrooms priced at 500 baht (£11.75) per kilogram and dried mushrooms at 5,000 bhat (£117) per kilogram.

READ MORE

STUDY ESTIMATES 5.5 MILLION IN THE US TAKE PSYCHEDELIC DRUGS

The use of psychedelic medicines has increased 30% since 2002, with the surge attributed to their therapeutic potential.

Read More

DOES MICRODOSING WORK? THE RESEARCH REMAINS CONFLICTED

While subjective experiences should not be dismissed, the efficacy of microdosing needs to be proven through clinical trials.

Read More

BUSINESS AND INVESTMENT

GH Research releases Q2 2022 financial results.

Freedom Biosciences receives US$10.5m in seed funding.

Awakn Life Sciences expands into Canada with licensing agreement.

Reunion Neuroscience starts trading on Toronto Stock Exchange.

Mydecine saved by US$250k private placement.

PharmAla to supply MDMA for Phase III trial in Australia.

SCIENCE AND RESEARCH

Psychedelic research and treatment-resistant depression.

Psychedelic medicines to treat addiction disorders.

LSD and psilocybin for migraine and cluster headaches.

The Psychedelics as Medicine Report provides market insights from industry experts.

With over 60,000 downloads, the flagship publication contains proprietary data for regulators, researchers and investors to make informed decisions.

Previous partners include atai Life Sciences, COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact [email protected]

CONTACT FORM

REGULATION AND LEGISLATION

Campaign for psilocybin access rights launched in the UK.

Psychiatrists oppose prohibition of psychedelic medicines.

Stigma may fall with decriminalisation in British Columbia.

California decriminalisation bill to return in 2023.

Psilocybin may be inaccessible in rural Oregon.

ARTICLES OF INTEREST

California governor unveils US$4.7bn youth mental health plan.

Axsome’s antidepressant receives FDA approval.

A history of psychedelic medicines in religion.